Filing Details

Accession Number:
0001209191-23-012001
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-22 20:05:55
Reporting Period:
2023-02-18
Accepted Time:
2023-02-22 20:05:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI Pharmaceutical Preparations (2834) 364742850
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1756211 Mark Neumann C/O Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Evp, Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-18 11,139 $0.00 56,478 No 4 M Direct
Common Stock Disposition 2023-02-21 3,140 $46.61 53,338 No 4 S Direct
Common Stock Disposition 2023-02-21 123 $47.32 53,215 No 4 S Direct
Common Stock Disposition 2023-02-21 635 $48.93 52,580 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-02-18 11,139 $0.00 11,139 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. Restricted stock units convert into common stock on a one-for-one basis.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.1267 to $47.1224, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.1591 to $47.5081, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.77 to $49.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  6. Each restricted stock unit represents a contingent right to receive one share of common stock.
  7. On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.